What Immunocore Holdings (IMCR)'s Phase 1 Brenetafusp Data and 160 mcg Dose Choice Means For Shareholders

Simply Wall St.06-01

Immunocore Holdings recently reported updated Phase 1 results for its TCR bispecific brenetafusp in heavily pretreated HLA-A*02:01-positive advanced melanoma, showing a 6‑month overall survival rate ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640193774?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-01 17:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640193774","market":"us","top_or_hot":-1,"title":"What Immunocore Holdings (IMCR)'s Phase 1 Brenetafusp Data and 160 mcg Dose Choice Means For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>Immunocore Holdings recently reported updated Phase 1 results for its TCR bispecific brenetafusp in heavily pretreated HLA-A*02:01-positive advanced melanoma, showing a 6‑month overall survival rate ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/what-immunocore-holdings-imcrs-phase-1-brenetafusp-data-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Immunocore Holdings (IMCR)'s Phase 1 Brenetafusp Data and 160 mcg Dose Choice Means For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Immunocore Holdings (IMCR)'s Phase 1 Brenetafusp Data and 160 mcg Dose Choice Means For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-01 17:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/what-immunocore-holdings-imcrs-phase-1-brenetafusp-data-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immunocore Holdings recently reported updated Phase 1 results for its TCR bispecific brenetafusp in heavily pretreated HLA-A*02:01-positive advanced melanoma, showing a 6‑month overall survival rate ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/what-immunocore-holdings-imcrs-phase-1-brenetafusp-data-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/what-immunocore-holdings-imcrs-phase-1-brenetafusp-data-and","article_id":"2640193774","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/what-immunocore-holdings-imcrs-phase-1-brenetafusp-data-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2640193774","pubTimestamp":1780305722,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Immunocore Holdings recently reported updated Phase 1 results for its TCR bispecific brenetafusp in heavily pretreated HLA-A*02:01-positive advanced melanoma, showing a 6‑month overall survival rate of 87% and a disease control rate of 52%, and confirming 160 mcg as the dose for the ongoing Phase 3 PRISM-MEL-301 trial.\nThis early signal of durable disease control in a difficult-to-treat melanoma population highlights how brenetafusp could broaden Immunocore’s oncology franchise beyond...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4023":"应用软件","AIPO":"Defiance AI and Power Infrastructure ETF","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4585":"ETF&股票定投概念","BK4528":"SaaS概念","BK4505":"高瓴资本持仓","AGIX":"通用人工智能 ETF-AGIX","BK4139":"生物科技","BK4142":"酒店、度假村与豪华游轮","BK4587":"ChatGPT概念","CHH":"精选国际酒店","IMCR":"Immunocore Holdings plc","BK4551":"寇图资本持仓","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4543":"AI","AI":"C3.ai, Inc.","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4588":"碎股"},"translate_title":"Immunocore Holdings(IMCR)的1期Brenetafusp数据和160 mcg剂量选择对股东意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AI":0.71,"CHAT":0.71,"AIYY":0.6,"IMCR":1.5,"AIPO":0.81,"CHH":1.5,"ARTY":0.71,"AGIX":0.71},"content_text":"Immunocore Holdings recently reported updated Phase 1 results for its TCR bispecific brenetafusp in heavily pretreated HLA-A*02:01-positive advanced melanoma, showing a 6‑month overall survival rate of 87% and a disease control rate of 52%, and confirming 160 mcg as the dose for the ongoing Phase 3 PRISM-MEL-301 trial. This early signal of durable disease control in a difficult-to-treat melanoma population highlights how brenetafusp could broaden Immunocore’s oncology franchise beyond KIMMTRAK if later-stage data eventually prove successful. We’ll now examine how the selection of a 160 mcg Phase 3 dose for brenetafusp may influence Immunocore’s investment narrative. Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementImmunocore Holdings Investment Narrative RecapTo own Immunocore, you need to believe its TCR platform can turn KIMMTRAK’s success into a broader, multi-drug oncology business before its lead asset matures. The updated Phase 1 brenetafusp data and selection of a 160 mcg dose feed directly into PRISM-MEL-301, which now looks like an even more important near term catalyst, while clinical or regulatory setbacks across the Phase 3 portfolio remain the central risk. The recent five year KIMMTRAK overall survival data at AACR 2026 are especially relevant here, because they reinforce the clinical backbone supporting Immunocore’s TCR approach just as brenetafusp moves into a pivotal setting. Together, durable KIMMTRAK outcomes and early brenetafusp signals frame a pipeline story where future data readouts, rather than near term earnings swings, are likely to shape how much value investors ultimately assign to Immunocore. Yet against this progress, the risk that expanding R&D for three Phase 3 trials strains margins for longer than investors expect is something you should be aware of... Read the full narrative on Immunocore Holdings (it's free!)Immunocore Holdings' narrative projects $551.3 million revenue and $88.5 million earnings by 2028.Uncover how Immunocore Holdings' forecasts yield a $66.57 fair value, a 130% upside to its current price.Exploring Other PerspectivesIMCR 1-Year Stock Price Chart Some of the lowest ranked analysts were assuming Immunocore’s revenue could shrink about 7.5% a year and still reach only around US$327.1 million by 2029, which is a much more pessimistic view than the idea that brenetafusp and other late stage assets could diversify the business, so this new melanoma data may eventually shift how you weigh these very different outlooks.Explore 3 other fair value estimates on Immunocore Holdings - why the stock might be worth over 8x more than the current price!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Immunocore Holdings research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Immunocore Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunocore Holdings' overall financial health at a glance.Ready To Venture Into Other Investment Styles?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640193774","isCrawlerRequest":true}